The introduction of the Immunomodulatory drugs (IMiDs) and proteasome inhibitors, used either as a single-agent or combined with classic anti-myeloma therapies, has improved the outcome for patients with relapsed myeloma. However, there is currently no generally accepted standard treatment for relapsed/refractory myeloma patients, partly because of the absence of trials comparing the efficacy of the novel agents in relapsed/refractory myeloma. Choice of a new treatment regimen depends on both patient and disease-specific characteristics. A lenalidomide-based regimen is the first choice in patients with neuropathy, while bortezomib has the highest efficacy in patients with renal insufficiency and is not associated with increased risk of thromboembolism. A second autologous stem cell transplantation (auto-SCT) can be applied in patients with a progression-free period of ≥18-24. months after the first auto-SCT. In high-risk relapse such as occurring early after auto-SCT consolidation with allogeneic SCT can be considered. In this review we provide an overview of the various salvage regimens and give recommendations for treatment of patients with relapsed/refractory myeloma in different clinical settings.

Additional Metadata
Keywords Bortezomib, Guidelines, Lenalidomide, Multiple myeloma, Novel agents, Refractory disease, Relapse treatment, Thalidomide
Persistent URL,
Journal Cancer Treatment Reviews
van de Donk, N.W.C.J, Lokhorst, H.M, Dimopoulos, M.A, Cavo, M, Morgan, G, Einsele, H, … Palumbo, A. (2011). Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 37(4), 266–283. doi:10.1016/j.ctrv.2010.08.008